Fennec Pharmaceuticals Q1 Revenue $15.1M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $15.1M, consensus $13.84M. "We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK across new patient populations and tumor types that reinforces our confidence in its broader potential," said Jeff Hackman, CEO of Fennec Pharmaceuticals. "At the same time, the strategic enhancements we've made to our field force are already sharpening our execution and expanding our reach - in tandem, the positive experiences we're seeing through our Fennec HEARS program are translating into meaningful access and strong conversion rates, resulting in more patients being treated. Coupled with our solid financial foundation, we believe we are well-positioned to continue to build momentum and deliver sustained growth throughout 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.890
Low
13.00
Averages
14.67
High
18.00
Current: 9.890
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fennec Pharmaceuticals Expands PEDMARK® Research Efforts
- Clinical Research Advancement: Fennec Pharmaceuticals will present four independent studies at the 2026 American Society of Clinical Oncology Annual Meeting, aimed at evaluating the application of PEDMARK® across diverse patient populations, further validating its clinical utility in adolescent and adult patients to address significant unmet medical needs.
- Significant Hearing Protection Effects: The STS-J01 study from the Japanese Children's Cancer Group demonstrated that among 27 patients aged 3-18 receiving PEDMARK®, the incidence of hearing loss was significantly reduced to 16-24%, compared to 56-63% in the control group, indicating PEDMARK®'s effectiveness in reducing chemotherapy-related hearing loss.
- Applicability in Adult Patients: A retrospective case series involving young adults aged 18-39 showed that PEDMARK® can be safely integrated with cisplatin without compromising its antitumor activity, demonstrating its feasibility in adult oncology workflows.
- Strategic Importance: Fennec Pharmaceuticals' research underscores the significance of PEDMARK® in cancer treatment and reflects the company's long-term commitment to improving patient quality of life, thereby enhancing focus on hearing protection post-chemotherapy.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On May 11, 2026, Fennec Pharmaceuticals approved the grant of 50,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing the company's competitive edge.
- Option Details: The granted stock options consist of 49,141 incentive stock options and 859 nonqualified stock options, with an exercise price of $9.75 per share, reflecting the closing price on March 15, 2026, and a ten-year term.
- Vesting Schedule: One-third of each stock option will vest on the one-year anniversary of the grant date, with monthly vesting thereafter over 24 months, designed to incentivize long-term employee retention and improve productivity.
- Market Strategy: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients, and the exclusive licensing agreement with Norgine is expected to further expand market coverage and strengthen the company's position in the global pharmaceutical market.
See More
Fennec Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Fennec Pharmaceuticals reported a Q1 GAAP EPS of $0.01, exceeding expectations by $0.04, indicating improved profitability and boosting investor confidence.
- Significant Revenue Growth: The company achieved revenues of $15.11 million in Q1, a 72.7% year-over-year increase, surpassing market expectations by $1.27 million, demonstrating strong demand for its PEDMARK® product.
- Strong Cash Position: As of March 31, 2026, Fennec's cash and cash equivalents stood at $40.1 million, up from $36.8 million as of December 31, 2025, reflecting effective cash management.
- Positive Future Outlook: The company anticipates that its cash, cash equivalents, and investment securities as of March 31, 2026, will be sufficient to fund its business based on the current operating plan, showcasing management's confidence in future revenues.
See More
Fennec Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fennec Pharmaceuticals plans to release its Q1 2026 financial results before the U.S. market opens on May 14, 2026, with management hosting a conference call and webcast to discuss financial and business outcomes, which is expected to positively impact investor confidence.
- Call Timing and Links: The conference call is scheduled for 8:30 a.m. Eastern Time on May 14, and investors can access the live webcast link via the company’s website, ensuring connection at least 15 minutes prior to avoid technical issues, demonstrating the company's commitment to transparency and investor communication.
- PEDMARK® Commercialization Progress: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with FDA approval in 2022 and subsequent approvals in Europe and the U.K. in 2023, marking a strategic positioning in the oncology market.
- Exclusive Licensing Agreement: In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, which will further enhance Fennec's international market presence and sales potential.
See More
Fennec Pharmaceuticals Showcases PEDMARK Research at ASCO Meeting
- Clinical Research Highlights: Fennec Pharmaceuticals announced that four abstracts on PEDMARK® were accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the drug's potential in preventing cisplatin-induced ototoxicity, which is expected to enhance the company's market position in oncology.
- Drug Indication: PEDMARK® is FDA-approved for pediatric patients aged one month and older to reduce the risk of ototoxicity associated with cisplatin treatment, receiving a 2A recommendation from the National Comprehensive Cancer Network (NCCN), underscoring its significance in pediatric oncology.
- Presentation Schedule: The four studies will be presented at the ASCO meeting from May 29 to June 2, 2026, including randomized trials for various cancer patients, which are anticipated to attract industry attention and drive the market promotion of PEDMARK.
- Impact of Ototoxicity: Ototoxicity affects 60-90% of patients treated with cisplatin, and the introduction of PEDMARK offers a new treatment option for these patients, expected to improve quality of life and reduce long-term healthcare costs.
See More
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
Fennec Pharmaceuticals Expands PEDMARK® Research Efforts
- Clinical Research Advancement: Fennec Pharmaceuticals will present four independent studies at the 2026 American Society of Clinical Oncology Annual Meeting, aimed at evaluating the application of PEDMARK® across diverse patient populations, further validating its clinical utility in adolescent and adult patients to address significant unmet medical needs.
- Significant Hearing Protection Effects: The STS-J01 study from the Japanese Children's Cancer Group demonstrated that among 27 patients aged 3-18 receiving PEDMARK®, the incidence of hearing loss was significantly reduced to 16-24%, compared to 56-63% in the control group, indicating PEDMARK®'s effectiveness in reducing chemotherapy-related hearing loss.
- Applicability in Adult Patients: A retrospective case series involving young adults aged 18-39 showed that PEDMARK® can be safely integrated with cisplatin without compromising its antitumor activity, demonstrating its feasibility in adult oncology workflows.
- Strategic Importance: Fennec Pharmaceuticals' research underscores the significance of PEDMARK® in cancer treatment and reflects the company's long-term commitment to improving patient quality of life, thereby enhancing focus on hearing protection post-chemotherapy.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On May 11, 2026, Fennec Pharmaceuticals approved the grant of 50,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing the company's competitive edge.
- Option Details: The granted stock options consist of 49,141 incentive stock options and 859 nonqualified stock options, with an exercise price of $9.75 per share, reflecting the closing price on March 15, 2026, and a ten-year term.
- Vesting Schedule: One-third of each stock option will vest on the one-year anniversary of the grant date, with monthly vesting thereafter over 24 months, designed to incentivize long-term employee retention and improve productivity.
- Market Strategy: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients, and the exclusive licensing agreement with Norgine is expected to further expand market coverage and strengthen the company's position in the global pharmaceutical market.
See More
Fennec Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Fennec Pharmaceuticals reported a Q1 GAAP EPS of $0.01, exceeding expectations by $0.04, indicating improved profitability and boosting investor confidence.
- Significant Revenue Growth: The company achieved revenues of $15.11 million in Q1, a 72.7% year-over-year increase, surpassing market expectations by $1.27 million, demonstrating strong demand for its PEDMARK® product.
- Strong Cash Position: As of March 31, 2026, Fennec's cash and cash equivalents stood at $40.1 million, up from $36.8 million as of December 31, 2025, reflecting effective cash management.
- Positive Future Outlook: The company anticipates that its cash, cash equivalents, and investment securities as of March 31, 2026, will be sufficient to fund its business based on the current operating plan, showcasing management's confidence in future revenues.
See More
Fennec Pharmaceuticals to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fennec Pharmaceuticals plans to release its Q1 2026 financial results before the U.S. market opens on May 14, 2026, with management hosting a conference call and webcast to discuss financial and business outcomes, which is expected to positively impact investor confidence.
- Call Timing and Links: The conference call is scheduled for 8:30 a.m. Eastern Time on May 14, and investors can access the live webcast link via the company’s website, ensuring connection at least 15 minutes prior to avoid technical issues, demonstrating the company's commitment to transparency and investor communication.
- PEDMARK® Commercialization Progress: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with FDA approval in 2022 and subsequent approvals in Europe and the U.K. in 2023, marking a strategic positioning in the oncology market.
- Exclusive Licensing Agreement: In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, which will further enhance Fennec's international market presence and sales potential.
See More
Fennec Pharmaceuticals Showcases PEDMARK Research at ASCO Meeting
- Clinical Research Highlights: Fennec Pharmaceuticals announced that four abstracts on PEDMARK® were accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the drug's potential in preventing cisplatin-induced ototoxicity, which is expected to enhance the company's market position in oncology.
- Drug Indication: PEDMARK® is FDA-approved for pediatric patients aged one month and older to reduce the risk of ototoxicity associated with cisplatin treatment, receiving a 2A recommendation from the National Comprehensive Cancer Network (NCCN), underscoring its significance in pediatric oncology.
- Presentation Schedule: The four studies will be presented at the ASCO meeting from May 29 to June 2, 2026, including randomized trials for various cancer patients, which are anticipated to attract industry attention and drive the market promotion of PEDMARK.
- Impact of Ototoxicity: Ototoxicity affects 60-90% of patients treated with cisplatin, and the introduction of PEDMARK offers a new treatment option for these patients, expected to improve quality of life and reduce long-term healthcare costs.
See More
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
